$783 Million is the total value of Rhenman & Partners Asset Management AB's 94 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 49.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | Sell | BioMarin Pharmaceutical Inc | $16,748,000 | -2.6% | 179,949 | -4.9% | 2.14% | -13.4% |
| UNH | Sell | United Health Group Inc | $16,647,000 | -0.2% | 85,000 | -5.6% | 2.12% | -11.3% |
| ESPR | Sell | Esperion Therapeutics Inc | $15,628,000 | -7.1% | 311,803 | -14.2% | 2.00% | -17.4% |
| INCY | Sell | Incyte Corp Ltd | $13,425,000 | -23.9% | 115,000 | -17.9% | 1.71% | -32.3% |
| NVCR | Sell | NovoCure Ltd Reg | $13,231,000 | -37.1% | 666,528 | -45.2% | 1.69% | -44.1% |
| GILD | Sell | Gilead Sciences Inc | $12,603,000 | -30.7% | 155,551 | -39.5% | 1.61% | -38.4% |
| JAZZ | Sell | Jazz Pharmaceuticals Plc | $12,431,000 | -6.0% | 85,000 | -0.0% | 1.59% | -16.4% |
| NVRO | Sell | Nevro Corp | $11,814,000 | +2.3% | 130,000 | -16.2% | 1.51% | -9.0% |
| LLY | Sell | Eli Lilly & Co | $9,409,000 | -23.8% | 110,000 | -26.7% | 1.20% | -32.2% |
| DVAX | Sell | Dynavax Technologies Corp | $8,053,000 | +42.1% | 374,537 | -36.2% | 1.03% | +26.3% |
| FGEN | Sell | FibroGen Inc | $7,828,000 | +57.0% | 145,500 | -5.7% | 1.00% | +39.5% |
| NBIX | Sell | Neurocrine Biosciences Inc | $7,047,000 | +27.7% | 115,000 | -4.2% | 0.90% | +13.5% |
| IMMU | Sell | Immunomedics Inc | $6,990,000 | +49.5% | 500,000 | -5.6% | 0.89% | +32.9% |
| BIIB | Sell | Biogen Inc | $6,889,000 | -47.7% | 22,000 | -54.6% | 0.88% | -53.5% |
| ELGX | Sell | Endologix Inc | $6,657,000 | -13.0% | 1,492,600 | -5.2% | 0.85% | -22.7% |
| LIVN | Sell | Livanova Plc | $6,656,000 | +6.8% | 95,000 | -6.7% | 0.85% | -5.0% |
| SNY | Sell | Sanofi spons ADR repr 0.5 Shareadr | $6,473,000 | -15.6% | 130,000 | -18.8% | 0.83% | -25.0% |
| MRK | Sell | Merck & Co Inc | $5,763,000 | -35.8% | 90,000 | -35.7% | 0.74% | -42.9% |
| XNCR | Sell | Xencor Inc | $5,730,000 | +4.6% | 250,000 | -3.7% | 0.73% | -7.1% |
| WBA | Sell | Walgreens Boots Alliance Inc | $5,405,000 | -31.0% | 70,000 | -30.0% | 0.69% | -38.6% |
| ALNY | Sell | Alnylam Pharmaceuticals Inc | $5,028,000 | -21.4% | 42,793 | -46.6% | 0.64% | -30.1% |
| EPZM | Sell | Epizyme Inc | $4,501,000 | +18.2% | 236,293 | -6.3% | 0.58% | +5.1% |
| OMCL | Sell | Omnicell Inc | $4,084,000 | +0.6% | 80,000 | -15.1% | 0.52% | -10.6% |
| HCA | Sell | HCA Healthcare Inc | $3,980,000 | -51.8% | 50,000 | -47.2% | 0.51% | -57.2% |
| KERX | Sell | Keryx Biopharmaceuticals Inc | $2,840,000 | -7.6% | 400,000 | -5.9% | 0.36% | -17.7% |
| RGLS | Sell | Regulus Therapeutic Inc | $725,000 | +23.9% | 580,000 | -2.3% | 0.09% | +10.7% |
| PFE | Sell | Pfizer Inc | $372,000 | -97.4% | 10,422 | -97.6% | 0.05% | -97.7% |
| ANTH | Exit | Anthera Pharmaceuticals Inc Reg | $0 | – | -25,000 | -100.0% | -0.01% | – |
| OPHT | Exit | Ophthotech Corp | $0 | – | -23,920 | -100.0% | -0.01% | – |
| THLD | Exit | Threshold Pharmaceuticals | $0 | – | -201,537 | -100.0% | -0.01% | – |
| MRTX | Exit | Mirati Therapeutics Inc | $0 | – | -50,000 | -100.0% | -0.03% | – |
| TNDM | Exit | Tandem Diabetes Care Inc | $0 | – | -234,000 | -100.0% | -0.03% | – |
| OREXQ | Exit | Orexigen Therapeutics Inc | $0 | – | -120,000 | -100.0% | -0.05% | – |
| OCUL | Exit | Ocular Therapeutix Inc | $0 | – | -40,000 | -100.0% | -0.05% | – |
| CNCE | Exit | Concert Pharm Inc | $0 | – | -30,099 | -100.0% | -0.06% | – |
| CATB | Exit | Catabasis Pharmaceuticals Inc | $0 | – | -310,756 | -100.0% | -0.06% | – |
| FWP | Exit | Forward Pharma A/S spons ADS Level III repr 1 Share | $0 | – | -36,584 | -100.0% | -0.11% | – |
| ACAD | Exit | Acadia Pharmaceuticals Inc | $0 | – | -30,000 | -100.0% | -0.12% | – |
| SUPN | Exit | Supernus Pharmaceuticals Inc | $0 | – | -30,000 | -100.0% | -0.19% | – |
| HALO | Exit | Halozyme Therapeutics Inc | $0 | – | -120,000 | -100.0% | -0.22% | – |
| PODD | Exit | Insulet Corp | $0 | – | -35,000 | -100.0% | -0.26% | – |
| TTPH | Exit | Tetraphase Pharmaceuticals Inc | $0 | – | -300,000 | -100.0% | -0.31% | – |
| LH | Exit | Laboratory Corp of America Hgs | $0 | – | -20,000 | -100.0% | -0.44% | – |
| ENDP | Exit | Endo International Plc | $0 | – | -277,303 | -100.0% | -0.44% | – |
| HOLX | Exit | Hologic Inc | $0 | – | -70,000 | -100.0% | -0.46% | – |
| DVA | Exit | DaVita Inc | $0 | – | -55,000 | -100.0% | -0.51% | – |
| CAH | Exit | Cardinal Health Inc | $0 | – | -55,000 | -100.0% | -0.62% | – |
| TMO | Exit | Thermo Fisher Scientific Inc | $0 | – | -25,000 | -100.0% | -0.63% | – |
| NXTM | Exit | NxStage Medical Inc | $0 | – | -213,901 | -100.0% | -0.77% | – |
| AMGN | Exit | Amgen Inc | $0 | – | -35,000 | -100.0% | -0.86% | – |
| KITE | Exit | Kite Pharma Inc | $0 | – | -60,000 | -100.0% | -0.89% | – |
| ZBH | Exit | Zimmer Biomet Hgs Inc | $0 | – | -90,000 | -100.0% | -1.66% | – |
| Exit | NeuroDerm Ltd | $0 | – | -461,654 | -100.0% | -1.98% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-10-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.